

## MEDIA COVERAGE

### Benzinga

- [Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab](#)

### BioSpace

- [KEYTRUDA® Plus LENVIMA® Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study](#)
- [Merck and Eisai's Keytruda-Lenvima Combo Dazzles in Endometrial Cancer Trial](#)
- [Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer](#)

### Business Wire

- [Clovis Oncology's Rubraca® \(rucaparib\) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation](#)

### Cancer Network

- [ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer](#)
- [Visible Residual Disease Following Interval Debulking in Ovarian Cancer Is Associated With Positive Outcomes With Niraparib](#)
- [Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer](#)
- [Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021](#)
- [Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer](#)
- [For Ovarian Cancer Treated With Olaparib/Bevacizumab, CA-125 Shows Promise for Identifying Disease Progression](#)
- [BJ Rimel, MD, Discusses Biggest Takeaways from 2021 SGO Annual Meeting](#)

### Healio

- [Survey: Most female gynecologic oncologists have faced workplace bullying, harassment](#)
- [Top in hem/onc: Harassment among female gynecologic oncologists, Keytruda approval](#)

### HealthDay

- [Drug Boosts Survival for Women With Advanced Ovarian Cancer](#)
- [An IUD Could Ward Off Endometrial Cancer in Women at Risk](#)

### Journal of Clinical Pathways

- [Pembrolizumab and Lenvatinib Use for Endometrial Cancer in Clinical Practice](#)
- [Medicare Reimbursement Trends for Gynecologic and Urologic Procedures](#)

## MEDIA COVERAGE

### MDEdge

- [Gynecologic cancer patients at risk of insurance loss, 'catastrophic' costs](#)

### MedPage Today

- [PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer](#)
- [Is MIS Viable for Interval Debulking in Ovarian Cancer?](#)
- [Hormonal IUD Shows Promise in Early Endometrial Cancer](#)
- [Androgen Receptor Inhibitor Active in Endometrial Cancer](#)
- [Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer](#)
- [Triage System Gets High Marks for Ovarian Cancer Debulking Surgery](#)

### Pharmacy Times

- [Hormonal IUD Shows Promise as an Effective Treatment for Early Endometrial Cancer or Precancer](#)
- [Study Demonstrates Promising Results for GEN-1 in Advanced Ovarian Cancer](#)
- [Study Finds Risk of Death Due to COVID-19 Not Raised by Recent Chemotherapy, Immunotherapy for Gynecologic Cancer](#)
- [Monotherapy Demonstrates Promising Clinical Activity in Endometrial Cancer](#)
- [Pembrolizumab Plus Lenvatinib Demonstrates Improved Overall Survival in Treatment of Advanced Endometrial Cancer](#)
- [Olaparib as Maintenance Drug Reduces Disease Progression for Advanced Ovarian Cancer](#)

### Targeted Oncology

- [The Rationale of Maintenance With Durvalumab With or Without Olaparib in Patients With Endometrial Cancer](#)

### The ASCO Post

- [Survey Reveals Workplace Bullying, Gender Discrimination, and Microaggressions Not Uncommon for Women Gynecologic Oncologists](#)
- [PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status](#)
- [Pembrolizumab/Lenvatinib May Improve Survival in Advanced Endometrial Cancer](#)

### Yahoo

- [Poster on Celsion Corporation's Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer](#)